Travere Therapeutics, Inc. (TVTX)
52.12
+0.08
(+0.16%)
USD |
NASDAQ |
Oct 09, 16:00
52.17
+0.04
(+0.09%)
After-Hours: 20:00
Travere Therapeutics Cash from Operations (Quarterly) : 58.07M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 58.07M |
| March 31, 2026 | -40.37M |
| December 31, 2025 | 60.68M |
| September 30, 2025 | 14.32M |
| June 30, 2025 | 4.983M |
| March 31, 2025 | -42.19M |
| December 31, 2024 | -35.72M |
| September 30, 2024 | -42.51M |
| June 30, 2024 | -40.24M |
| March 31, 2024 | -119.00M |
| December 31, 2023 | -70.47M |
| September 30, 2023 | -59.13M |
| June 30, 2023 | -69.30M |
| March 31, 2023 | -81.12M |
| December 31, 2022 | -54.64M |
| September 30, 2022 | -39.52M |
| June 30, 2022 | -36.81M |
| March 31, 2022 | -55.32M |
| December 31, 2021 | -26.88M |
| September 30, 2021 | 32.06M |
| June 30, 2021 | 6.496M |
| March 31, 2021 | -26.47M |
| December 31, 2020 | -13.87M |
| September 30, 2020 | 6.735M |
| June 30, 2020 | -6.453M |
| Date | Value |
|---|---|
| March 31, 2020 | -29.16M |
| December 31, 2019 | -4.492M |
| September 30, 2019 | -14.12M |
| June 30, 2019 | -19.11M |
| March 31, 2019 | -20.49M |
| December 31, 2018 | -3.565M |
| September 30, 2018 | -3.899M |
| June 30, 2018 | -2.76M |
| March 31, 2018 | -14.73M |
| December 31, 2017 | -0.854M |
| September 30, 2017 | 6.198M |
| June 30, 2017 | 4.835M |
| March 31, 2017 | -2.776M |
| December 31, 2016 | -6.763M |
| September 30, 2016 | 4.744M |
| June 30, 2016 | 3.99M |
| March 31, 2016 | -3.567M |
| December 31, 2015 | -2.549M |
| September 30, 2015 | 1.429M |
| June 30, 2015 | 7.899M |
| March 31, 2015 | -7.333M |
| December 31, 2014 | -9.094M |
| September 30, 2014 | -15.50M |
| June 30, 2014 | -11.45M |
| March 31, 2014 | -9.806M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 39.26M |
| BioMarin Pharmaceutical, Inc. | 168.11M |
| Vertex Pharmaceuticals, Inc. | 1.125B |
| Viridian Therapeutics, Inc. | -105.32M |
| Krystal Biotech, Inc. | 74.79M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -206.29M |
| Cash from Financing (Quarterly) | 187.52M |
| Free Cash Flow | 15.40M |
| Free Cash Flow Per Share (Quarterly) | 0.3958 |
| Free Cash Flow to Equity (Quarterly) | -252.24M |
| Free Cash Flow to Firm (Quarterly) | 39.12M |
| Free Cash Flow Yield | 0.31% |